The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis
Open Access
- 5 July 2017
- journal article
- review article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (32) , 53631-53641
Abstract
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> De-Dong Cao1, Hui-Lin Xu2, Xi-Ming Xu1 and Wei Ge1 1Department of oncology, RenMin Hospital of Wuhan University, Wuhan, China 2Department of oncology, The fifth hospital of Wuhan, Wuhan, China Correspondence to: Wei Ge, email: gewei514@126.com Xi-Ming Xu, email: doctorxu120@aliyun.com Keywords: primary tumor location, cetuximab, colorectal cancer, Kras, meta-analysis Received: August 10, 2016 Accepted: June 20, 2017 Published: July 05, 2017 ABSTRACT Objective: To assess the prognostic role of primary tumor location along with Kras status in metastatic colorectal cancer (mCRCs) treated with cetuximab. Materials and Methods: Databases of EMBASE, Pubmed, the Cochrane library, China National Knowledge Infrastructure and other databases from inception to July 2016 were searched. Randomized controlled trial (RCT) and/or retrospective studies of influence of primary tumor location on efficacy of cetuximab in patients with mCRC were identified. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), overall response rate (ORR) and disease control rate (DCR). Results: Ten studies including 2977 cases were finally included. The results of meta-analysis were in favor of cetuximab to patients with left-sided colorectal cancer in terms of OS (HR = 0.52, 95% CI: 0.40–0.66; p < 0.01), PFS (HR = 0.64, 95% CI: 0.58–0.70; p < 0.01), and ORR (OR = 2.17, 95% CI: 1.57–2.99; p < 0.01). Patients with right-sided CRC gained less benefit from cetuximab in terms of OS (HR = 1.89, 95% CI: 1.43–2.50; p < 0.01), compared with left-sided CRC. Regarding Kras status, left-sided mCRC with wild type Kras had better PFS (HR = 0.61, 95% CI: 0.51–0.74; p < 0.01) and OS (HR = 0.49, 95% CI: 0.35–0.69; p < 0.01) than right-sided cases when treated with cetuximab. We also found that cetuximab was both significantly effective in different treatment lines and regions when comparing by primary tumor locations (p < 0.01). Conclusions: mCRC Patients with left-sided, wild type Kras have a better prognosis than those with right-sided diseases when treated with cetuximab. The clinical application of cetuximab should be determined by the primary tumor location and molecular gene mutation status.Keywords
This publication has 30 references indexed in Scilit:
- Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal CancerJournal of Clinical Oncology, 2015
- Right- and left-sided colorectal cancers respond differently to cetuximabChinese Journal of Cancer, 2015
- Is right-sided colon cancer different to left-sided colorectal cancer? – A systematic reviewEuropean Journal of Surgical Oncology, 2015
- Different treatment strategies and molecular features between right-sided and left-sided colon cancersWorld Journal of Gastroenterology, 2015
- Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trialThe Lancet Oncology, 2014
- Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trialJournal of Cancer Research and Clinical Oncology, 2014
- Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trialThe Lancet Oncology, 2014
- A meta analysis of cetuximab plus oxaliplatin based chemotherapy regimen for metastatic colorectal cancerIndian Journal of Cancer, 2014
- No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-AnalysisPLOS ONE, 2012
- Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studiesEuropean Journal of Cancer, 2010